Last reviewed · How we verify
NCT07104591
TETRAVI Expanded Access Program
trial testing HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes) in Epstein-Barr Virus Infection. Available.
Quick facts
| Lead sponsor | Baylor College of Medicine |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes) — full drug profile →
Conditions studied
- Epstein-Barr Virus Infection — all drugs for Epstein-Barr Virus Infection →
- Cytomegalovirus Infections — all drugs for Cytomegalovirus Infections →
- Adenovirus Infection — all drugs for Adenovirus Infection →
- BK Virus Infection — all drugs for BK Virus Infection →
Sponsor
Baylor College of Medicine
Who can join
Under 17, any sex, with Epstein-Barr Virus Infection or Cytomegalovirus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07104591
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epstein-Barr Virus Infection
Currently open trials in the same condition.
- NCT07368634 — Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 1, PHASE2 · recruiting
- NCT06908096 — Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With · Phase 1 · recruiting
- NCT05683834 — Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV · Phase 1, PHASE2 · active not recruiting
- NCT05831111 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants · Phase 1 · active not recruiting
- NCT04645147 — Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or W · Phase 1 · active not recruiting
Other Baylor College of Medicine trials
Trials by the same sponsor.
- NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
- NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
- NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
- NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
- NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07104591 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104591.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing